Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.

摘要: To examine the effect of diagnosis year, defined as contemporary (2010–2014), intermediate (2006–2009) and historical (2001–2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). Within Surveillance, Epidemiology, End Results registry (2001–2014), we identified mRCC. Cumulative incidence competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality. Finally, performed subgroup analyses according to histological subtype: clear-cell mRCC (ccmRCC) versus non-ccmRCC. We 15,444 Of those, 41.0, 28.7 30.3% were diagnosed, respectively, contemporary, years. all, 47.1, 5.3 47.6% were, ccmRCC, non-ccmRCC other variants [sarcomatoid mRCC, cyst-associated collecting duct not otherwise specified (NOS)]. Overall, 24-month CSM rates 61.0, 63.7 67.3% patients. In all patients, multivariable CRR exhibited higher (HR 1.11; p < 0.001) 1.24; than Multivariable focusing ccmRCC yielded virtually same results. However, showed no differences year (all p ≥ 0.3). The introduction new therapeutic agents resulted CSM-free survival improvement over study time. this exclusively applies but those This observation is agreement established efficacy systemic therapies lesser these